The Department of Health and Human Being Services and Department of Defense have awarded $1.6 billion to Novavax and $450 million to Regeneron Pharmaceuticals as part of the federal government’s efforts to speed up the development of coronavirus treatments.
The bottom line: Federal researchers are holding out hope that these companies’ treatments, together with other vaccines in advancement, will off the spread of the coronavirus.
Details: Both awards are part of the Trump administration’s Operation Warp Speed.
- In exchange for the $1.6 billion, the federal government will own 100 million dosages of Novavax’s vaccine, which is still in early testing but has shown some appealing body immune system reaction.
- The $450 million to Regeneron is for increased production of an antibody drug that is being evaluated as a way to both reward and avoid infection
- More details about whether these drugs are safe and effective will come out in the fall.